

May 28, 2020



## Poxel Announces Participation in Upcoming Virtual Investor Conferences

LYON, France--(BUSINESS WIRE)-- [POXEL SA](https://www.poxel.com) (Euronext: POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative treatments for metabolic disorders, including type 2 diabetes and non-alcoholic steatohepatitis (NASH), today announced that members of the Poxel management team will participate in several upcoming virtual investor conferences held in June 2020.

### Jefferies Virtual Healthcare Conference 2020

**Date:** June 2-4, 2020

Thomas Kuhn, CEO, will present a corporate overview on Wednesday, June 3, 2020 from 9:30 to 9:55 am EDT. Members of the Poxel management team will be available for one-on-one virtual meetings.

To access the webcast, please visit: <http://www.wsj.com/webcast/jeff126/poxel.pa/>. The webcast replay will remain available for 90 days following the live presentation.

### Citi European Virtual Healthcare Conference 2020

**Date:** June 16-17, 2020

Members of the Poxel management team will be available for one-on-one virtual meetings.

### Forum MIDCAPS Gilbert Dupont

**Date:** June 18, 2020

Members of the Poxel management team will be available for one-on-one virtual meetings.

### About Poxel SA

Poxel is a **dynamic biopharmaceutical company** that uses its extensive expertise in developing **innovative drugs for metabolic diseases**, with a focus on **type 2 diabetes** and **non-alcoholic steatohepatitis (NASH)**. In its mid-to-late stage pipeline, the Company is currently advancing three drug candidates as well as earlier-stage opportunities. **Imeglimin**, Poxel's first-in-class lead product, targets mitochondrial dysfunction. Together, with its partner Sumitomo Dainippon Pharma, Poxel successfully completed the Phase 3 Trials of **IMeglimin** for **Efficacy** and **Safety** (TIMES) program for the treatment of type 2 diabetes in Japan. Poxel also established a partnership with Roivant Sciences for Imeglimin's development and commercialization in countries outside of the partnership with Sumitomo Dainippon Pharma, including the U.S. and Europe. **PXL770**, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is in a Phase 2a proof-of-concept program for the treatment of NASH. PXL770 could also have the potential to treat additional metabolic diseases. **PXL065** (deuterium-stabilized R-pioglitazone), a mitochondrial pyruvate

carrier (MPC) inhibitor, is advancing into a Phase 2 clinical trial for the treatment of NASH. Poxel also has additional earlier-stage programs targeting metabolic, specialty and rare diseases. The Company intends to generate further growth through strategic partnerships and pipeline development. Listed on Euronext Paris, Poxel is headquartered in Lyon, France, and has subsidiaries in Boston, MA, and Tokyo, Japan. For more information, please visit: [www.poxelpharma.com](http://www.poxelpharma.com).

In the context of the COVID-19 outbreak, which was declared a pandemic by the World Health Organization (WHO) on March 12, 2020, the Company has undertaken a full review of the impact of the outbreak on its business. Considering the rapidly evolving situation, the Company is updating this assessment on a regular basis.

The Company anticipates that the COVID-19 pandemic could have a material negative impact on its business operations. The worldwide impact of COVID-19 may notably affect the Company's internal organization and efficiency, particularly in countries where it operates and where confinement measures have been implemented by the authorities. In addition, the deteriorating market conditions may impact the Company's ability to raise additional funding and/or to enter into partnerships. Particularly, delays in the supply of drug substance or drug products, in pre-clinical and/or clinical trials, as well as delays linked to the responsiveness of regulatory authorities could occur, which could potentially have an impact on the Company's development programs. The Company will continue to proactively monitor the situation.

All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by or including words such as "target," "believe," "expect," "aim," "intend," "may," "anticipate," "estimate," "plan," "project," "will," "can have," "likely," "should," "would," "could" and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.

View source version on businesswire.com:

<https://www.businesswire.com/news/home/20200528005488/en/>

## **Poxel SA**

Jonae R. Barnes

Senior Vice President, Investor Relations, Corporate Communications and Public Relations

[jonae.barnes@poxelpharma.com](mailto:jonae.barnes@poxelpharma.com)

+1 617 818 2985

Aurélié Bozza

Investor Relations & Communication Director

[aurelie.bozza@poxelpharma.com](mailto:aurelie.bozza@poxelpharma.com)

+33 6 99 81 08 36

## **Investor relations / Media - EU/US**

Trophic Communications

Joanne Tudorica or Valeria Fisher

[tudorica@trophic.eu](mailto:tudorica@trophic.eu) or [fisher@trophic.eu](mailto:fisher@trophic.eu)  
+49 171 351 2733 or +49 175 804 1816

**Investor relations / Media - France**

NewCap

Emmanuel Huynh or Arthur Rouillé

[poxel@newcap.eu](mailto:poxel@newcap.eu)

+33 1 44 71 94 94

Source: Poxel SA